CRISPR Therapeutics Casgevy Sales Surge 78% QoQ to $76M Following FDA Expansion
Question
CRISPR Therapeutics Casgevy Sales Surge 78% QoQ to $76M Following FDA Expansion
Direct answer
CRISPR Therapeutics reported second-quarter commercial progress for Casgevy, its approved CRISPR/Cas9 gene-editing therapy co-developed with Vertex Pharmaceuticals. Product revenue grew 78% sequentially to $76 million, demonstrating patient uptake across authorized treatment centers. Commercial momentum received support from FDA approval of a label expansion authorizing Casgevy for pediatric patients aged 2 and older. The expanded indication broadens the accessible patient pool for sickle cell disease and transfusion-dependent beta-thalassemia. — bullish pressure on CRSP.
- Original publisher
- Market Ontology
- Evidence through
- 2026-09-09
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “CRISPR Therapeutics Casgevy Sales Surge 78% QoQ to $76M Following FDA Expansion”, revision 1, evidence through 2026-09-09. https://marketontology.com/catalysts/2026-09-09/crispr-therapeutics-casgevy-sales-surge-78-qoq-to-76m-following-fda-expansion-8d4143
CRISPR Therapeutics Casgevy Sales Surge 78% QoQ to $76M Following FDA Expansion
CRISPR Therapeutics reported second-quarter commercial progress for Casgevy, its approved CRISPR/Cas9 gene-editing therapy co-developed with Vertex Pharmaceuticals. Product revenue grew 78% sequentially to $76 million, demonstrating patient uptake across authorized treatment centers. Commercial momentum received support from FDA approval of a label expansion authorizing Casgevy for pediatric patients aged 2 and older. The expanded indication broadens the accessible patient pool for sickle cell disease and transfusion-dependent beta-thalassemia. — bullish pressure on CRSP.
CRISPR Therapeutics reported second-quarter commercial progress for Casgevy, its approved CRISPR/Cas9 gene-editing therapy co-developed with Vertex Pharmaceuticals. Product revenue grew 78% sequentially to $76 million, demonstrating patient uptake across authorized treatment centers. Commercial momentum received support from FDA approval of a label expansion authorizing Casgevy for pediatric patients aged 2 and older. The expanded indication broadens the accessible patient pool for sickle cell disease and transfusion-dependent beta-thalassemia.
- SummaryCRISPR Therapeutics reported second-quarter commercial progress for Casgevy, its approved CRISPR/Cas9 gene-editing therapy co-developed with Vertex Pharmaceuticals. Product revenue grew 78% sequentially to $76 million, demonstrating patient uptake across authorized treatment centers. Commercial momentum received support from FDA approval of a label expansion authorizing Casgevy for pediatric patients aged 2 and older. The expanded indication broadens the accessible patient pool for sickle cell disease and transfusion-dependent beta-thalassemia.
- CRSPDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- CRSP closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- CRSP price vs. pre-event level
- CRSP volume vs. 20-day average
CRISPR Therapeutics Casgevy Sales Surge 78% QoQ to $76M Following FDA Expansion
CRISPR Therapeutics reported second-quarter commercial progress for Casgevy, its approved CRISPR/Cas9 gene-editing therapy co-developed with Vertex Pharmaceuticals. Product revenue grew 78% sequentially to $76 million, demonstrating patient uptake across authorized treatment centers. Commercial momentum received support from FDA approval of a label expansion authorizing Casgevy for pediatric patients aged 2 and older. The expanded indication broadens the accessible patient pool for sickle cell disease and transfusion-dependent beta-thalassemia. — bullish pressure on VRTX.
CRISPR Therapeutics reported second-quarter commercial progress for Casgevy, its approved CRISPR/Cas9 gene-editing therapy co-developed with Vertex Pharmaceuticals. Product revenue grew 78% sequentially to $76 million, demonstrating patient uptake across authorized treatment centers. Commercial momentum received support from FDA approval of a label expansion authorizing Casgevy for pediatric patients aged 2 and older. The expanded indication broadens the accessible patient pool for sickle cell disease and transfusion-dependent beta-thalassemia.
- SummaryCRISPR Therapeutics reported second-quarter commercial progress for Casgevy, its approved CRISPR/Cas9 gene-editing therapy co-developed with Vertex Pharmaceuticals. Product revenue grew 78% sequentially to $76 million, demonstrating patient uptake across authorized treatment centers. Commercial momentum received support from FDA approval of a label expansion authorizing Casgevy for pediatric patients aged 2 and older. The expanded indication broadens the accessible patient pool for sickle cell disease and transfusion-dependent beta-thalassemia.
- VRTXDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- VRTX closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- VRTX price vs. pre-event level
- VRTX volume vs. 20-day average
What happened next
| Asset | Call | Base close | +1 day | +5 days | +20 days |
|---|---|---|---|---|---|
| VRTX | Bullishdisagreed | 521.12 2026-09-09 | -1.26% | -1.51% | Pending |
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related catalysts
- 2026-09-24Vertex Reports Phase IIb Data for Inaxaplin with 42.7% Proteinuria Drop in AMKDVRTX-2.99%
- 2026-09-24Vertex Reports Positive Phase IIb Kidney Disease Data for InaxaplinVRTX-2.99%
- 2026-09-24Vertex Inaxaplin Phase IIb Cuts Proteinuria in Kidney Disease TrialVRTX-2.99%
- 2026-09-24Vertex reports positive Phase IIb inaxaplin results for kidney diseaseVRTX-2.99%
- 2026-09-24Vertex Inaxaplin Phase IIb Cuts Proteinuria in Kidney Disease TrialVRTX-2.99%
- 2026-09-24Vertex Reports Positive Phase IIb Kidney Disease Data for InaxaplinVRTX-2.99%
- 2026-09-24Vertex reports positive Phase IIb inaxaplin results for kidney diseaseVRTX-2.99%
- 2026-09-24Vertex Reports Phase IIb Data for Inaxaplin with 42.7% Proteinuria Drop in AMKDVRTX-2.99%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.